Risk factors and disease associations in people living with idiopathic intracranial hypertension

References

• Yiangou A, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: a step change in understanding the disease mechanisms. Nat Rev Neurol. 2023 Dec;19(12):769–785. doi: 10.1038/s41582-023-00893-0
   PubMed Web of Science ®Google Scholar
• Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019;76(9):1088–1098. doi: 10.1001/jamaneurol.2019.1812
   PubMed Web of Science ®Google Scholar
• Shaia JK, Sharma N, Kumar M, et al. Changes in prevalence of idiopathic intracranial hypertension in the United States between 2015 and 2022, stratified by sex, race, and ethnicity. Neurology. 2024 Feb 13;102(3):e208036. doi: 10.1212/WNL.0000000000208036
   PubMedGoogle Scholar
• Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018;89(10):1088–1100. doi: 10.1136/jnnp-2017-317440
   PubMed Web of Science ®Google Scholar
• Mollan SP, Wakerley BR, Alimajstorovic Z, et al. Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. J Headache Pain. 2021;22(1):118. doi: 10.1186/s10194-021-01321-8
   PubMed Web of Science ®Google Scholar
• Mollan SP, Subramanian A, Perrins M, et al. Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: A matched controlled cohort study. Headache. 2023 Feb;63(2):290–298. doi: 10.1111/head.14465
   PubMed Web of Science ®Google Scholar
• Thaller M, Homer V, Mollan SP, et al. Asymptomatic idiopathic intracranial hypertension: Prevalence and prognosis. Clin Exp Ophthalmol. 2023 Aug;51(6):598–606. doi: 10.1111/ceo.14256
   PubMed Web of Science ®Google Scholar
• Hyder YF, Homer V, Thaller M, et al. Defining The phenotype and prognosis of people with idiopathic intracranial hypertension after cerebrospinal fluid diversion surgery. Am J Ophthalmol. 2023 Jun;250:70–81. doi: 10.1016/j.ajo.2023.01.016
   PubMed Web of Science ®Google Scholar
• Mollan SP, Mytton J, Tsermoulas G, et al. Idiopathic intracranial hypertension: evaluation of admissions and emergency readmissions through the hospital episode statistic dataset between 2002-2020. Life (Basel). 2021 May 5;11(5):417. doi: 10.3390/life11050417
   PubMed Web of Science ®Google Scholar
• Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension. Eye (Lond). 2019 Mar;33(3):478–485. doi: 10.1038/s41433-018-0238-5
   PubMed Web of Science ®Google Scholar
• Lyons HS, Mollan SLP, Liu GT, et al. Different characteristics of pre-pubertal and post-pubertal idiopathic intracranial hypertension: a narrative review. Neuroophthalmology. 2022 Dec 15;47(2):63–74. doi: 10.1080/01658107.2022.2153874
   PubMed Web of Science ®Google Scholar
• Mollan S, Hemmings K, Herd CP, et al. What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open. 2019 Mar 15;9(3):e026573. doi: 10.1136/bmjopen-2018-026573
   PubMed Web of Science ®Google Scholar
• Tariq K, Toma A, Khawari S, et al. Cerebrospinal fluid production rate in various pathological conditions: a preliminary study. Acta Neurochir (Wien). 2023 Aug;165(8):2309–2319. doi: 10.1007/s00701-023-05650-2
   PubMed Web of Science ®Google Scholar
• Wardman JH, Jensen MN, Andreassen SN, et al. Modelling idiopathic intracranial hypertension in rats: contributions of high fat diet and testosterone to intracranial pressure and cerebrospinal fluid production. Fluids Barriers CNS. 2023 Jun 16;20(1):44. doi: 10.1186/s12987-023-00436-1
   PubMed Web of Science ®Google Scholar
• Trevisi G, Frassanito P, Di Rocco C. Idiopathic cerebrospinal fluid overproduction: case-based review of the pathophysiological mechanism implied in the cerebrospinal fluid production. Croat Med J. 2014;55(4):377–387. doi: 10.3325/cmj.2014.55.377
   PubMed Web of Science ®Google Scholar
• Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021 Jun 1;78(6):678–686. doi: 10.1001/jamaneurol.2021.0659
   PubMed Web of Science ®Google Scholar
• Tan MG, Worley B, Kim WB, et al. Drug-induced intracranial hypertension: a systematic review and critical assessment of drug-induced causes. Am J Clin Dermatol. 2020 Apr;21(2):163–172. doi: 10.1007/s40257-019-00485-z PMID: 31741184.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Chong YJ, Grech O, et al. Current perspectives on idiopathic intracranial hypertension without papilloedema. Life (Basel). 2021 May 24;11(6):472. doi: 10.3390/life11060472
   PubMed Web of Science ®Google Scholar
• Klein A, Stern N, Osher E, et al. Hyperandrogenism is associated with earlier age of onset of idiopathic intracranial hypertension in women. Curr Eye Res. 2013 Sep;38(9):972–976. doi: 10.3109/02713683.2013.799214
   PubMed Web of Science ®Google Scholar
• Hornby C, Mollan SP, Mitchell J, et al. What do transgender patients teach us about idiopathic intracranial hypertension? Neuroophthalmology. 2017 May 10;41(6):326–329. doi: 10.1080/01658107.2017.1316744
   PubMedGoogle Scholar
• O’Reilly MW, Westgate CS, Hornby C, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight. 2019 Mar 21;4(6):e125348. doi: 10.1172/jci.insight.125348
   PubMed Web of Science ®Google Scholar
• Daniels AB, Liu GT, Volpe NJ, et al. Profiles of obesity, weight gain, and quality of life in idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol. 2007 Apr;143(4):635–641. doi: 10.1016/j.ajo.2006.12.040
   PubMed Web of Science ®Google Scholar
• Thaller M, Homer V, Abbott S, et al. Does a healthy weight body mass index at onset of idiopathic intracranial hypertension change the outcomes? A United Kingdom prospective cohort study. Neuro-Ophthalmology. 2024:1–12. doi: 10.1080/01658107.2024.2341775
   PubMedGoogle Scholar
• Hornby C, Botfield H, O’Reilly MW, et al. Evaluating the fat distribution in idiopathic intracranial hypertension using dual-energy X-ray absorptiometry scanning. Neuroophthalmology. 2017 Jun 20;42(2):99–104. doi: 10.1080/01658107.2017.1334218
   PubMedGoogle Scholar
• Abdelghaffar M, Hussein M, Abdelkareem SA, et al. Sex hormones, CSF and serum leptin in patients with idiopathic intracranial hypertension. Egypt J Neurol Psychiatry Neurosurg. 2022;58(1):39. doi: 10.1186/s41983-022-00473-x
   Google Scholar
• Westgate CS, Botfield HF, Alimajstorovic Z, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight. 2021 May 24;6(10):e145346. doi: 10.1172/jci.insight.145346 PMID: 33848268; PMCID: PMC8262372.
   PubMed Web of Science ®Google Scholar
• Ball AK, Sinclair AJ, Curnow SJ, et al. Elevated cerebrospinal fluid (CSF) leptin in idiopathic intracranial hypertension (IIH): evidence for hypothalamic leptin resistance? Clin Endocrinol (Oxf). 2009 Jun;70(6):863–869. doi: 10.1111/j.1365-2265.2008.03401.x
   PubMed Web of Science ®Google Scholar
• Markey K, Mitchell J, Botfield H, et al. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Com. [2020 Jan 10];2(1):fcz050. doi: 10.1093/braincomms/fcz050
   PubMedGoogle Scholar
• Westgate CSJ, Markey K, Mitchell JL, et al. Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension. Eur J Endocrinol. 2022 Jul 4;187(2):323–333. doi: 10.1530/EJE-22-0108
   PubMed Web of Science ®Google Scholar
• Sandeep TC, Andrew R, Homer NZ, et al. Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes. 2005 Mar;54(3):872–879. doi: 10.2337/diabetes.54.3.872
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Walker EA, Burdon MA, et al. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation? J Clin Endocrinol Metab. 2010 Dec;95(12):5348–5356. doi: 10.1210/jc.2010-0729
   PubMed Web of Science ®Google Scholar
• Edwards LJ, Sharrack B, Ismail A, et al. Increased levels of interleukins 2 and 17 in the cerebrospinal fluid of patients with idiopathic intracranial hypertension. Am J Clin Exp Immunol. [2013 Oct 16];2(3):234–244.
   PubMedGoogle Scholar
• Eshtiaghi A, Margolin EA, Micieli JA. Idiopathic Intracranial Hypertension and Socioeconomic Status in the Greater Toronto Area, Canada. J Neuroophthalmol. 2023 Jun;43(2):197–201. doi: 10.1097/WNO.0000000000001680
   PubMed Web of Science ®Google Scholar
• Health inequalities briefing obesity and weight management: a briefing for nice guideline developers and committee members february 2023 national institute of health and clinical excellence. [cited 2024 Mar 11]. Available from: https://www.nice.org.uk/guidance/cg189/documents/health-inequalities-briefing
   Google Scholar
• Kesler A, Mosek A, Fithlicher N, et al. Psychological correlates of idiopathic intracranial hypertension. Isr Med Assoc J. 2005 Oct;7(10):627–630.
   PubMed Web of Science ®Google Scholar
• Witry M, Kindler C, Weller J, et al. The patients’ perspective on the burden of idiopathic intracranial hypertension. J Headache Pain. 2021 Jul 8;22(1):67. doi: 10.1186/s10194-021-01283-x
   PubMed Web of Science ®Google Scholar
• Hermes SM, Miller NR, Waslo CS, et al. Mortality among patients with idiopathic intracranial hypertension enrolled in the IH Registry. Neurology. 2020 Aug 18;95(7):e921–e929. doi: 10.1212/WNL.0000000000009312
   PubMed Web of Science ®Google Scholar
• Sugita Y, Iijima S, Teshima Y, et al. Marked episodic elevation of cerebrospinal fluid pressure during nocturnal sleep in patients with sleep apnea hypersomnia syndrome. Electroencephalogr Clin Neurophysiol. 1985;60(3):214–219. doi: 10.1016/0013-4694(85)90033-1
   PubMedGoogle Scholar
• Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol. 2000;118(12):1626–1630. doi: 10.1001/archopht.118.12.1626
   PubMedGoogle Scholar
• Thurtell MJ, Trotti LM, Bixler EO, et al. Obstructive sleep apnea in idiopathic intracranial hypertension: comparison with matched population data. J Neurol. 2013 Jul;260(7):1748–1751. doi: 10.1007/s00415-013-6858-6
   PubMed Web of Science ®Google Scholar
• Youssef M, Sundaram ANE, Veitch M, et al. Obstructive sleep apnea in those with idiopathic intracranial hypertension undergoing diagnostic in-laboratory polysomnography. Sleep Med. 2024 Feb;114:279–289. doi: 10.1016/j.sleep.2024.01.013
   PubMed Web of Science ®Google Scholar
• Yiangou A, Mitchell JL, Nicholls M, et al. Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). J Neurol. 2022 Apr;269(4):1945–1956. doi: 10.1007/s00415-021-10700-9
   PubMed Web of Science ®Google Scholar
• Grewal N, Gordon D, Bajaj S, et al. Impact of obstructive sleep apnea treatment on cardiovascular disease associated mortality and morbidity: a systematic review. Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102139. doi: 10.1016/j.cpcardiol.2023.102139
   PubMed Web of Science ®Google Scholar
• Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology. 2002 Nov 26;59(10):1492–1495. doi: 10.1212/01.wnl.0000029570.69134.1b PMID: 12455560.
   PubMed Web of Science ®Google Scholar
• Plant GT, Wong SH, Sundholm A, et al. Idiopathic intracranial hypertension and anemia: a matched case-control study. J Neuroophthalmol. 2021 Jun 1;41(2):e272–e273. doi: 10.1097/WNO.0000000000001183
   PubMed Web of Science ®Google Scholar
• Yu CW, Waisberg E, Kwo JM, et al. Anemia and idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neuroophthalmol. 2022 Mar;42(1):e78–e86. doi: 10.1097/WNO.0000000000001408
   PubMed Web of Science ®Google Scholar
• Mollan SP, Ball AK, Sinclair AJ, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009;62(2):105–108. doi: 10.1159/000222781
   PubMed Web of Science ®Google Scholar
• Thaller M, Homer V, Sassani M, et al. Longitudinal prospective cohort study evaluating prognosis in idiopathic intracranial hypertension patients with and without comorbid polycystic ovarian syndrome. Eye (Lond). 2023 Dec;37(17):3621–3628. doi: 10.1038/s41433-023-02569-x
   PubMed Web of Science ®Google Scholar
• Thaller M, Adderley NJ, Subramanian A, et al. Co-morbid polycystic ovarian syndrome with idiopathic intracranial hypertension. Neuroophthalmology. 2023 Jan 10;47(1):49–52. doi: 10.1080/01658107.2022.2162089
   PubMed Web of Science ®Google Scholar
• Horowitz BZ. Did hypervitaminosis a have a role in Mawson’s ill-fated Antarctic exploration? Clin Toxicol (Phila). 2022 Nov;60(11):1277–1281. doi: 10.1080/15563650.2022.2128366
   PubMed Web of Science ®Google Scholar
• Fraunfelder FW. Ocular side effects associated with isotretinoin. Drugs Today (Barc). 2004 Jan;40(1):23–27. doi: 10.1358/dot.2004.40.1.799435
   PubMed Web of Science ®Google Scholar
• Libien J, Kupersmith MJ, Blaner W, et al. NORDIC Idiopathic Intracranial Hypertension Study Group. Role of vitamin a metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci. 2017 Jan 15;372:78–84. doi: 10.1016/j.jns.2016.11.014
   PubMed Web of Science ®Google Scholar
• Thaller M, Mytton J, Wakerley BR, et al. Idiopathic intracranial hypertension: Evaluation of births and fertility through the hospital episode statistics dataset. BJOG. 2022 Nov;129(12):2019–2027. doi: 10.1111/1471-0528.17241
   PubMed Web of Science ®Google Scholar
• Thaller M, Homer V, Mollan SP, et al. Disease course and long-term outcomes in pregnant women with idiopathic intracranial hypertension: the iih prospective maternal health study. Neurology. 2023 Apr 11;100(15):e1598–e1610. doi: 10.1212/WNL.0000000000206854
   PubMed Web of Science ®Google Scholar
• Thaller M, Wakerley BR, Abbott S, et al. Managing idiopathic intracranial hypertension in pregnancy: practical advice. Pract Neurol. 2022 Aug;22(4):295–300. doi: 10.1136/practneurol-2021-003152
   PubMedGoogle Scholar
• Mollan SP, Grech O, Alimajstorovic Z, et al. New horizons for idiopathic intracranial hypertension: advances and challenges. Br Med Bull. 2020 Dec 15;136(1):118–126. doi: 10.1093/bmb/ldaa034
   PubMed Web of Science ®Google Scholar
• Piccus R, Thaller M, Sinclair AJ, et al. Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension. Expert Rev Neurother. 2023 May;23(5):457–466. doi: 10.1080/14737175.2023.2206567
   PubMed Web of Science ®Google Scholar
• Abbott S, Chan F, Tahrani AA, et al. Weight management interventions for adults with idiopathic intracranial hypertension: a systematic review and practice recommendations. Neurology. 2023 Nov 21;101(21):e2138–e2150. doi: 10.1212/WNL.0000000000207866
   PubMed Web of Science ®Google Scholar
• Ko MW, Chang SC, Ridha MA, et al. Weight gain and recurrence in idiopathic intracranial hypertension: a case-control study. Neurology. 2011 May 3;76(18):1564–1567. doi: 10.1212/WNL.0b013e3182190f51 PMID: 21536635.
   PubMed Web of Science ®Google Scholar
• Mollan SP, Mitchell JL, Yiangou A, et al. Association Of amount of weight lost after bariatric surgery with intracranial pressure in women with idiopathic intracranial hypertension. Neurology. 2022 Sep 13;99(11):e1090–e1099. doi: 10.1212/WNL.0000000000200839
   PubMed Web of Science ®Google Scholar
• Alimajstorovic Z, Mitchell JL, Yiangou A, et al. Determining the role of novel metabolic pathways in driving intracranial pressure reduction after weight loss. Brain Com. 2023 Oct 18;5(5):fcad272. doi: 10.1093/braincomms/fcad272
   PubMedGoogle Scholar
• Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023 May 2;146(5):1821–1830. doi: 10.1093/brain/awad003
   PubMed Web of Science ®Google Scholar
• Khatkar P, Hubbard JC, Hill L, et al. Experimental drugs for the treatment of idiopathic intracranial hypertension (IIH): shedding light on phase I and II trials. Expert Opin Investig Drugs. 2023 Jul;32(12):1123–1131. doi: 10.1080/13543784.2023.2288073
   PubMed Web of Science ®Google Scholar
• Abbott S, Denton A, Wong SH, et al. Weight management communications in idiopathic intracranial hypertension: challenges and recommendations from the patients’ perspective. BMJ Neurol Open. 2023 Dec 9;5(2):e000527. doi: 10.1136/bmjno-2023-000527
   PubMedGoogle Scholar
• Hardy RS, Botfield H, Markey K, et al. 11βHSD1 inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension. J Clin Endocrinol Metab. 2021 Jan 1;106(1):174–187. doi: 10.1210/clinem/dgaa766 PMID: 33098644; PMCID: PMC7765633.
   PubMed Web of Science ®Google Scholar
• Adderley NJ, Subramanian A, Perrins M, et al. Headache, opiate use, and prescribing trends in women with idiopathic intracranial hypertension: a population-based matched cohort study. Neurology. 2022 Oct 31;99(18):e1968–e1978. doi: 10.1212/WNL.0000000000201064
   PubMed Web of Science ®Google Scholar
• Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641–1651. doi: 10.1001/jama.2014.3312
   PubMed Web of Science ®Google Scholar
• Menon V, Hansen MS, Mollan SP. Fulminant idiopathic intracranial hypertension should be redefined without a time limited definition. Neuro-Ophthalmology. 2024;1–3. doi: 10.1080/01658107.2024.2337165
   PubMedGoogle Scholar
• Gurney SP, Ramalingam S, Thomas A, et al. Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting. Eye Brain. 2020;12:1–13. doi: 10.2147/EB.S193027
   PubMed Web of Science ®Google Scholar
• Khunte M, Chen H, Colasurdo M, et al. National trends of cerebral venous sinus stenting for the treatment of idiopathic intracranial hypertension. Neurology. 2023;101(9):402–406. doi: 10.1212/WNL.0000000000207245
   PubMed Web of Science ®Google Scholar
• Mollan SP, Fraser CL, Digre KB, et al. Guidelines of the international headache society for controlled clinical trials in idiopathic intracranial hypertension. Cephalalgia. 2023 Aug;43(8):3331024231197118. doi: 10.1177/03331024231197118
   Web of Science ®Google Scholar
• Hoffmann J, Mollan SP, Paemeleire K, et al. European headache federation guideline on idiopathic intracranial hypertension. J Headache Pain. 2018 Oct 8;19(1):93. doi: 10.1186/s10194-018-0919-2
   PubMedGoogle Scholar
• Thaller M, Homer V, Hyder Y, et al. The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 2023 Feb;270(2):851–863. doi: 10.1007/s00415-022-11402-6 Epub 2022 Oct 15. PMID: 36242625; PMCID: PMC9886634.
   PubMed Web of Science ®Google Scholar
• Thaller M, Tsermoulas G, Sun R, et al. Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2021 Jul;92(7):795–797. doi: 10.1136/jnnp-2020-325519
   PubMed Web of Science ®Google Scholar
• Pruckner P, Mitsch C, Macher S, et al. The vienna idiopathic intracranial hypertension database-an austrian registry. Wien Klin Wochenschr. 2024 Jan;136(1–2):32–39. doi: 10.1007/s00508-023-02252-x
   PubMedGoogle Scholar
• Sundholm A, Burkill S, Sveinsson O, et al. Population-based incidence and clinical characteristics of idiopathic intracranial hypertension. Acta Neurol Scand. 2017 Nov;136(5):427–433. doi: 10.1111/ane.12742
   PubMed Web of Science ®Google Scholar
• Vijay V, Mollan SP, Mitchell JL, et al. Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMA Ophthalmol. 2020 Dec 1;138(12):1264–1271. doi: 10.1001/jamaophthalmol.2020.4242
   PubMed Web of Science ®Google Scholar